scorecardresearchZydus Lifesciences Share Price Live NSE, BSE, Today - Zydus Lifesciences
Mintgenie
Asian Paints3,251.25-0.75 (-0.02%)
Axis Bank1,118.00-2.20 (-0.20%)
Bajaj Finance7,394.30-32.20 (-0.43%)
Bajaj Finserve1,703.853.75 (0.22%)
Bharti Airtel998.75-25.20 (-2.46%)
HCL Technologies1,327.20-2.45 (-0.18%)
HDFC Bank1,630.603.40 (0.21%)
Hindustan Unilever2,520.00-46.10 (-1.80%)
ICICI Bank999.35-3.60 (-0.36%)
ITC458.10-4.90 (-1.06%)
Indusind Bank1,508.408.80 (0.59%)
Infosys1,466.15-7.95 (-0.54%)
Kotak Mahindra Bank1,826.356.10 (0.34%)
Larsen & Toubro3,360.75-30.85 (-0.91%)
Mahindra & Mahindra1,693.70-8.75 (-0.51%)
Maruti Suzuki India10,689.9064.40 (0.61%)
NTPC284.052.90 (1.03%)
Nestle India25,010.0048.25 (0.19%)
Power Grid Corporation Of India229.855.45 (2.43%)
Reliance Industries2,457.60-3.10 (-0.13%)
State Bank Of India611.853.75 (0.62%)
Sun Pharmaceutical Industries1,239.50-0.45 (-0.04%)
Tata Consultancy Services3,616.7013.35 (0.37%)
Tata Motors721.90-0.50 (-0.07%)
Tata Steel130.00-1.80 (-1.37%)
Tech Mahindra1,223.30-2.15 (-0.18%)
Titan Company3,585.6538.85 (1.10%)
Ultratech Cement9,359.65149.50 (1.62%)
Wipro418.20-0.65 (-0.16%)

Zydus Lifesciences

BSE: 532321 | NSE: ZYDUSLIFE | ISIN: INE010B01027 | SECTOR: Biotechnology & Drugs

₹658.20 22.90 (3.6%)

07 Dec 2023, 10:21 (IST)

  • Open

    641.95

  • High

    659.65

  • Low

    635.00

  • Prev Close

    635.30

  • P/E

    -

  • Median P/E

    -

  • P/B

    -

  • Median P/B

    -

  • Market Cap

    666.23B

  • Volume

    57.24K

  • Vol. (20 day Avg.)

    0

  • PEG

    -

  • Div.Yield

    -

  • Bid

    658.20

  • Ask

    -
View all metrics

Company Description

  • Biotechnology & Drugs

  • BSE

    532321

  • NSE

    ZYDUSLIFE

  • ISIN

    INE010B01027

Zydus Lifesciences Ltd. is an India-based life sciences company. The Company is engaged in the research and development, manufacturing, marketing and selling of finished dosage human formulations, such as generics and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients (APIs); animal healthcare products, and consumer wellness products. Its products include Bilypsa (saroglitizar), Oxemia (desidustat), Ujvira (biosimilar Kadcyla), and Exemptia. It offers Bilypsa drug for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Desidustat is an oral, small molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor, which is used for the treatment of anemia in chronic kidney disease (CKD) patients. It is also developing an oral small molecule ZYIL1, targeted at selectively suppressing inflammation caused by the NLRP3 inflammasome. Its ZyCoV-D is a plasmid deoxyribonucleic acid (DNA) vaccine for COVID-19.

Company Officers

  • Nitin Parekh

    Chief Financial Officer

  • Dhaval Soni

    Company Secretary, Chief Compliance Officer

  • Sharvil Patel

    Managing Director, Executive Director

  • Ganesh Nayak

    Executive Director